Job Description – Senior Manager/Manager –Project Evaluation

Position Objectives:

- Responsible for working closely with other relevant functions to (i) conduct comprehensive and in-depth scientific/market evaluations of potential in-licensing and investment assets that fit company's development strategy; (ii) coordinate cross-functional due diligence teams to efficiently assess M&A, in-licensing and co-devlopment opportunities; (iii) prepare comprehensive project feasibility report for SMT to make informative decisions
- Responsible for performing intelligence gathering and continuously updating a comprehensive industry landscape on selected targets
- Working in close partnerships with other BD team members to identify and drive major in-licensing and research alliance opportunities that deliver upon the external innovation strategies of the company.

Position Accountabilities:

- Proactively monitor commercial, clinical, and IP landscapes for all external discovery- and development-stage innovations that address relevant to the company's pipeline and BD strategies.
- Conduct in-depth scientific evaluations of potential collaboration opportunities at discovery-, development- and commercial-stages and present the analyses to the company's BD team leader.
- Support the company's BD team on partnering activities in terms of technical expertise and due diligence, coordinating technical evaluation and due diligence teams and develop professional, thorough and insightful analyses/presentations/proposals/reports for the company's senior management team.

Position Qualifications:

- Master's degree in a biological (pharmacology/biology/biochemistry/chemistry) discipline is required; Ph.D. degree is preferred.
- Must demonstrate scientific knowledge to hold/drive meaningful scientific discussions with industrial and academic experts.
- Creative, results-oriented self-starter with the ability to deliver on time and manage multiple assignments simultaneously.
- Strong interpersonal, verbal and written communication skills in both Chinese and English.
- Pharmaceutical industry working experience is preferred.

Betta Pharmaceuticals Co., Ltd. (SZ300558), established in 2003 in Hangzhou, China, is one of the leading Chinese pharmaceutical companies dedicated to develop and commercialize innovative oncology products to meet high unmet medical needs. With over 1,300 employees in Hangzhou and Beijing, China, Betta's development capabilities range from small molecule and biologics discovery, clinical development, registration, manufacturing, sales and marketing.

Betta's leading product – icotinib (Conmana®), the first innovative oncology product developed and commercially launched by a Chinese pharmaceutical company – is the No.1-selling targeted therapy treating non-small cell lung cancer patients carrying EGFR mutations in China, having achieved 1.21 billion RMB annual sales in 2018.

Betta currently has two programs under NDA review by the NMPA, three programs under late-stage clinical development, three programs under proof-of-concept clinical development, two programs under IND review by the NMPA and close to twenty programs under pre-clinical development. Betta has set up joint ventures with Amgen Inc. (AMGN) and Tyrogenex Inc. and is the majority shareholder of Xcovery LLC.